15 YEARS

GenomeQuébec

ANNUAL REPORT – SPECIAL EDITION



ANNUAL REPORT 2014-2015



SUMMARY

ABOUT US

GenomeQuébec

MISSION

In partnership with national and international leaders in life sciences, Génome Québec contributes to strengthening the competitiveness of the genomics innovation system in order to maximize its socioeconomic impact in Québec, by funding major genomic research initiatives and putting in place the tools necessary for scientific and strategic development in the field.

SPECIAL THANKS TO OUR PARTNERS

GenomeCanada

Économie, Innovation et Exportations Québec

CORPORATE INFORMATION

For more information, please contact
Éva Kammer, Director, Communications
at 514 398-0668 ext. 206 or by email
at ekammer@genomequebec.com

Head office Génome Québec
630 René-Lévesque Blvd. West, Suite 2660
Montréal, Québec H3B 1S6
514 398-0668
Fax: 514 398-0883
genomequebec.com

Auditors – KPMG L.L.P.
600 de Maisonneuve Blvd. West, Suite 1500
Montréal, Québec H3A 0A3
kpmg.com

Legal Counsel
Jean Brunet, Attorney
Stein Monast, L.L.P.
70 Dalhousie Street, Suite 300
Québec, Québec G1K 4B2
steinmonast.ca

Génome Canada
150 Metcalfe Street, Suite 2100
Ottawa, Ontario K2P 1P1
genomecanada.ca

Ministère de l'Économie, de l'Innovation et des Exportations
1035 De La Chevrotière
Québec, Québec G1R 5A5
economie.gouv.qc.ca

McGill University and Génome Québec Innovation Centre
740 Docteur-Penfield Avenue
Montréal, Québec H3A 1A4
514 398-7211
Fax: 514 398-1790
gqinnovationcenter.com

Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank
305 St-Vallier Street
Chicoutimi, Québec G7H 5H6
514 398-7211
infoservices@genomequebec.com

ISBN 978-2-9811988-5-3
Legal deposit – Bibliothèque et Archives nationales du Québec, 2015
Legal deposit – Library and Archives Canada, 2015

MESSAGE FROM THE CHAIR OF THE BOARD

MARTIN GODBOUT

CHAIR OF THE BOARD

"Fifteen years ago, a small group of scientists and policy makers took the audacious step of pushing back the limits to look far into the future. These people had a vision: one in which Canada would assume a role at the forefront of knowledge, and Québec would be a global leader in innovation."

This vision led to the creation of Genome Canada and shortly after, of Génome Québec. The year 2000 heralded both the new millennium and the dawn of the genomics revolution. Although the great adventure had only just begun, we already knew that in a few short years, it would spread with the force of a tsunami.

"Today, I am about to sequence my entire personal genome. I should be able to achieve the same result as in 2003 in only a few days for a few thousand dollars. A few years from now, we should be able to do it in just a few hours for a few hundred dollars, or maybe less."

Since that time, we have amassed an enormous store of knowledge, we have learned to master genomic technology and to decode the information it generates. Canada, and Québec in particular, has moved to the head of the pack, and now enjoys an envied position as one of the world's foremost players. More than two billion dollars have been invested to date in genomics research in Canada. This technology has made great strides since our 2003 announcement that we had succeeded in sequencing an entire human genome, which, as you will recall, cost three billion dollars over a period of 10 years.

"We are in the midst of a revolution and our modern society will need to take advantage of all this increasingly accessible knowledge. What will be the impact of this breakthrough technology on our daily lives? I predict that it will force us to do things differently."

Any form of change is met with resistance and that will probably be our challenge for the next fifteen years. However, in the same way as we slowly integrated information technologies into our daily lives until they became indispensable, genomics will become just as indispensable as it too gradually becomes an accepted part of our lives.

The effectiveness of healthcare depends on integrating innovations. Several of these will be created by genomics and will have a major impact on how medicine is practiced. In addition, genomics has the distinction of being a transversal competence. In fact, its impact will extend far beyond medicine, because genomic expertise can be deployed wherever there is life, whether it be our forests, our environment, or our food. It is a safe bet that many of the solutions to the problems associated to climate change will come from genomics.

"The social and economic future of Québec lies in innovation. It is at the same time a vector of economic development and a powerful force for change for a company such as ours. Let us continue to be daring and focus on making Québec a global centre for the development of innovative technologies and applications."

MESSAGE FROM THE PRESIDENT AND CEO

MARC LEPAGE
PRESIDENT AND CEO

"In the last fifteen years, we have traced a path from research to economic development. At first, our portfolio was composed almost entirely of human health projects, centred mostly on basic research. Our funding came from two sources only: 50 percent from Genome Canada and 50 percent from the Québec government."

Today, Québec has developed an enviable critical mass of expertise in genomics, and thanks to efforts undertaken since 2000, our researchers are successfully making the transition to applications. Also, the transfer and use of technologies developed for human genomics are now accelerating progress in the agrifood, forestry and environmental sectors. Our portfolio, which was centred almost exclusively on human health, is now far more diversified. The same goes for the way our funding model has evolved: we now have three sources of cash inflow, the third being the private sector at 33 percent.

GENOMICS AND ECONOMIC DEVELOPMENT

In its present mature form, genomics is a vector of progress and an incubator for solutions. It is a powerful tool for finding solutions to a wide range of problems. In fact, the potential impact of genomics on crops and livestock is as great as that on human biology and health. For example, genomics will make it possible to:

- **decode entire genomes in record time, at increasingly affordable costs. This will lead to the development of safe biopesticides, or to the creation of tools to facilitate the traceability of food, crops and livestock;**

- **identify microbial strains specific to Québec cheeses, to better understand how they develop and eventually, to control the manufacturing process;**

- **plant trees that are optimal for each location, depending on sunlight conditions, water availability, risks of infestation, etc. An optimal forest is one that grows fast and well because it is planted with the most productive varieties that are most exactly suited to local conditions.**

Of course, such a diversification of fields of application raises its own challenges, particularly in terms of mobilizing the public, whether in the industrial, government, or scientific domains. This will certainly be one of our greatest challenges in the coming years: to demystify what we do and to communicate it through our partnerships with industry and government regulatory agencies. Since the results are so compelling, we will make sure to spread the good news where it will do most good.

It is a fact: the economic benefits of the investments we have made to date are increasingly being felt. This tendency will continue to gain momentum in the coming years. We owe our existence to governments and to the people of Québec, who have supported this strategic sector for the past fifteen years. Over the next fifteen years, Québec will congratulate itself for having the vision and patience to support genomics.

We wish to thank our financial partners for their confidence and the Members of the Board for their cooperation and well-considered advice. We also thank the management team for contributing every day toward achieving our goals. Finally, where would we be without our valued employees? Special thanks to all of you for putting your skills to the service of this great adventure.

ACTIVITY REPORT

SCIENTIFIC AFFAIRS

CATALINA LÓPEZ CORREA

VICE PRESIDENT, SCIENTIFIC AFFAIRS

"Genome Canada has launched several competitions and research programs this year that emphasized on exploring sectors other than human health."

SUPPORT TO THE SCIENTIFIC COMMUNITY: A MODEL THAT HAS PROVEN ITSELF

Our primary challenge was to perform in the areas of agrifood, energy and natural resources, which meant that we had to explore new networks in the university, private and other sectors.

As a result of the personalized health competition in 2013, we were able to set up a support model that has proven its effectiveness to the research community. This year, we applied this model not only to other activity sectors, but also to potential users in the private and public domains. The initiatives undertaken by our team included consulting experts in specialized domains, conducting multiple meetings with representatives of the business and research communities and networking throughout the year.

By refining and clarifying our support model, the team has carved itself a special role as a bridge between industry and the research community. We believe we have developed a new capability for getting closer to the public and private sectors in order to harmonize their needs with what is happening in scientific research. Québec's excellent performance in Genome Canada's competitions, with their increasing emphasis on applications, provides incontestable proof of this.

"This year was marked by great success in competitions, particularly for the Genomic Application Partnership Program (GAPP), which was created to foster partnerships between academic researchers and users from industry."

OUR EFFORTS HAVE PAID OFF

Several projects are already under way as part of this program:

- Agropur dairy cooperative, with the project *Metagenomic method of evaluating the influence of cheesemaking technology and ripening conditions on the microbial ecosystem of premium quality washed rind soft cheeses*, in partnership with Steve Labrie of INAF - Université Laval.
- Elanco Company, with the project *Feedstock Optimization: development and marketing of a next generation enzyme supplement for pigs and poultry*, in partnership with Adrian Tsang, Center for Functional and Structural Genomics - Concordia University.

GENOMICS INNOVATION NETWORK COMPETITON: QUÉBEC STANDS OUT

Genome Canada revisited its technology platform funding strategy with a view to increasing the diversity of advanced technologies and making them more accessible to researchers. The Genomics Innovation Network (GIN) was launched to set up a network of different areas of expertise. Four Québec groups were chosen out of a total of ten across Canada, which represents a Genome Canada investment of approximately $5 million, or one third of available federal funding.

Philip Awadalla - CHU Sainte-Justine – Université de Montréal
Canadian Data Integration Centre
The Canadian Data Integration Centre offers comprehensive bioinformatics support for the collection, harmonization, analysis and electronic publication of data to help researchers understand the causes of human diseases and find ways to prevent and treat them.

Guillaume Bourque - McGill University
Computational Genomics Centre of Canada
The Canadian Centre for Computational Genomics facilitates access to bioinformatics and computational resources for researchers in life sciences to help them realize the potential of genomic research.

Mark Lathrop - McGill University and Génome Québec Innovation Centre
Founded in 2002, the McGill University and Génome Québec Innovation Centre is recognized worldwide for its expertise in complex conditions such as heart disease. It draws on this expertise in developing epigenomic applications aimed at better understanding human diseases.

Pierre Thibault - Institute for Immunology and Cancer Research at Université de Montréal
Advanced Proteomics Analysis Centre
The Advanced Proteomics Analysis Centre is a multidisciplinary institution that provides ground-breaking proteomic technologies to facilitate the development of immunotherapies against cancer and the discovery of cellular regulatory mechanisms based on interactions between proteins and post-translational modifications.

PREPARED FOR THE CHALLENGES AHEAD

These successes are proof of the excellence of Québec's researchers, but they also show that the impact of genomics is not limited to the health sector. Due to our team's structuring efforts to ensure that expertise is maintained in a variety of sectors, we are able to break into new areas for genomics and support our researchers' successes. Our philosophy is now much more focused on openness to both industry and academia in order to maximize the potential of genomics as a solution to society's needs. In the coming year, our efforts will be geared toward preparing for the launch of winning projects for the Genome Canada competition entitled *Genomics and Feeding the Future*.

ACTIVITY REPORT
TECHNOLOGY CENTRES

DANIEL TESSIER
VICE PRESIDENT, TECHNOLOGY CENTRES

"The Centre now has a total of 18 HiSeq instruments in addition to seven other types of next generation sequencers and can count on a generous grant from the Canadian Innovation Foundation to establish the first HiSeq-Xten platform in Canada. This platform will be accessible to the scientific community and will propel Québec and Canada toward a more integrated adoption of human genome sequencing."

MCGILL UNIVERSITY AND GÉNOME QUÉBEC INNOVATION CENTRE

Number of research teams supported in 2014-2015:
924 teams from 30 countries
2014-2015 revenue: **$16.2 million** */ Up* **8%** *over last year.*



User satisfaction level: **95%**

In the twelve years of the Innovation Centre's existence:
- *Number of research teams supported:* **2,581**
- *Revenue:* **$128 million**

Crowning a great deal of effort and development, the Centre has been newly accredited as a Certified Service Provider for sequencing using the Pacific Biosciences platform.

GÉNOME QUÉBEC AND CHU SAINTE-JUSTINE INTEGRATED PEDIATRIC CLINICAL GENOMIC CENTRE

The Centre's primary mandate is to perform clinical genomic analyses in order to explore monogenic diseases and childhood cancers. Since over 80% of rare genetic diseases occur in childhood or adolescence, it is expected that genome sequencing will have a significant impact in pediatrics. The Centre also seeks to support genomic research projects, with priority given to clinical translational projects.

The year was marked by the creation of a team and the installation of the equipment as part of the Clinical Genomic Centre's startup activities. During this period, the first analyses were carried out in the clinical exome project. In the coming months, we will attempt to increase the Centre's analytical capacity through the addition of new equipment, development of bioinformatic resources and optimization of laboratory processes.

"Since the official start of operations in August 2014,
the Centre has seen the completion of some 20 research projects
by a dozen of its collaborators."

The sequencing platform led by Jacques L. Michaud is the heart of CHU Sainte-Justine's rare genetic disease centre announced in February 2015, which is designed to better integrate clinical expertise with research and teaching on mitochondrial diseases.

GÉNOME QUÉBEC AND CHAUR BIOBANK

The Biobank has completed the storage of the 17,000 samples from the second wave of CARTaGENE participants and processed over 15,000 transactional sample requests. In addition to proposing a number of conditions for storing biological samples, including the only GenVault infrastructure in North America for room temperature storage, the Biobank also offers DNA and RNA extraction services, biochemical analyses and consultation on customized storage at clients' sites.

CARTaGENE

Philip Awadalla has published half a dozen high-level articles in prestigious journals such as *PLOS Genetics, EMBO, Science* and most recently, two in *Nature*. These articles attest to the great value of this population-based cohort, which contains over 40,000 biological samples and phenotypic data.

GENIZON BIOBANK

The Génome Québec research ethics committee has completed its work aimed at defining the protocol for the use of the Genizon population-based cohort by the research community. The procedures for accessing the biological samples and clinical records of some 45,000 participants from 27 different medical cohorts will be announced in the near future.

ACTIVITY REPORT

PUBLIC AFFAIRS AND COMMUNICATIONS

MARIE-KYM BRISSON

VICE PRESIDENT, PUBLIC AFFAIRS AND COMMUNICATIONS

"As a vector of economic development, genomics leads us to explore various sectors other than health, including agrifood, forestry, natural resources and the environment."

Since the creation of Génome Québec, issues in public affairs and communications have undergone fundamental changes. In fact, the rapid evolution of genomic technologies has generated its share of challenges, including the diversification of its fields of application and the multiplication of audiences. A few short years ago, our goal was to reach the scientific community, specialized media and the government department in charge of innovation. Today, we must also reach industry, end users, all departments affected by genomic applications, mass media and the general public. As a result, we must now rethink the manner in which we function.



The addition of these new sectors requires a good dose of creativity and a willingness to step outside our comfort zone, whether it comes to strategy or to the resources at our disposal to address this new reality.

Another noteworthy challenge this year was, of course, the new team elected at the helm of the Government. We have had to start from scratch with an entirely new network of stakeholders, most of whom are unfamiliar with genomics.

FOCUSING OUR EFFORTS WHERE IT MATTERS MOST

"Creating and seizing opportunities has become our new motto. Due to budget restrictions, each and every action we take must reach more than one target."

With this in mind, we have developed partnerships with the BÉNÉFIQ congress, organized by the Institute of Nutrition and Functional Foods (INAF), and the Strategic Forum on Natural Resources, hosted by the Board of Trade of Metropolitan Montreal. These initiatives, which allowed us to mobilize key stakeholders in agrifood and natural resources, have yielded beneficial results in terms of spinoffs and outreach, including new collaborations and financing opportunities.

We have also maintained our presence on the international stage. For instance, we took advantage of the Québec Premier's visit to London to announce a major partnership between Oxford and Laval universities in forest genomics. In addition, our President and CEO was invited to participate in the Canadian Prime Minister's mission to Dakar as part of the Francophone Summit. Then, as a member of the Québec delegation to the BIO 2014 International Convention, Génome Québec launched a charm offensive for postdoctoral students living in California. A dozen of them accepted our invitation and some have shown an interest in returning to Québec to work. We were also present at the conference of the American Association for the Advancement of Science, which gave us a wonderful opportunity for sharing information and networking with scientific journalists. Shortly after, we enjoyed excellent coverage when the results of the Genomic Applications Partnership Program were announced.

GENOMICS MAKING HEADLINES

In terms of media coverage, highlights this year included the research teams of Guy Sauvageau, of the Institute for Research in Immunology and Cancer (IRIC) and of John MacKay, of Université Laval, who made the annual list of the top ten discoveries in *Québec Science*. The work of Guy Sauvageau was then selected as the year's "Favourite Discovery" by the readership of the magazine. One month later, Radio-Canada named him the 2014 scientist of the year. Congratulations!

Finally, special thanks go out to the researchers for their tremendous availability whenever they are asked to take part in public activities. They are great ambassadors of genomics and our best spokespeople to reach key audiences. Their involvement makes a huge contribution to the development of genomics in Québec.



2,414 *subscribers*

966 *followers*

904 *subscribers*

+ 13.75 % *more visitors*

ACTIVITY REPORT

HUMAN RESOURCES AND LEGAL SERVICE

ÈVE-STÉPHANIE SAUVÉ

DIRECTOR, HUMAN RESOURCES AND LEGAL SERVICE

"The past year in human resources has been marked by Génome Québec's concern with offering its employees a work environment that ensures retention of personnel while attracting the best candidates."



Our objective is to promote our employees' quality of life, and in so doing, to benefit the organization. By ensuring that its employees are satisfied, Génome Québec will become a more productive workplace that is better able to retain its highly qualified personnel. It is for this reason that we are going ahead with an update of our human resources management practices and adapting management policies to bring them in line with employees' expectations. The labour market is changing, and workers' aspirations are increasingly focused on improving conditions in their working life, through flexible schedules, recognition programs, ongoing training and the sense of belonging. Génome Québec has responded creatively, both in terms of working conditions and personnel development programs.

A MAJOR CHALLENGE FOR THE LEGAL SERVICE DEPARTMENT

On the legal front, much effort and many resources have been mobilized to support the numerous competitions announced over the course of the year. The numerous Québec projects that have been chosen in Genome Canada competitions have increased the workload at legal services, which had to be flexible in arriving at satisfactory agreements for all the partners.

Governance represents an ongoing task for the Legal Service department, which has to remain on the lookout for changes that affect our sector and ensure that Génome Québec is compliant. This work calls for constant monitoring to meet the organization's high standards of compliance and ethics.

VALUATION OF GÉNOME QUÉBEC'S ASSETS

The past year was also marked by an in-depth review of our intellectual property portfolio, a project that was undertaken with the Scientific Affairs department with the aim of evaluating Génome Québec's assets. A major initiative aimed at highlighting and marketing the intellectual property resulting from research is currently under way.

Génome Québec at the Genome Games in Montréal

ACTIVITY REPORT

FINANCE

CLAUDE LAMARRE

VICE PRESIDENT, FINANCE

"Génome Québec receives most of its financial support from Genome Canada and the Québec government for the funding of research projects and the operation of its technology centres."

As at March 31, 2015, our research portfolio included 30 genomic projects, and three technology centres are currently in operation. Génome Québec invested $57.4 million during the 2014-2015 fiscal year. This amount, combined with the $27.1 million invested by other partners, brings our overall injection of funds to $84.5 million, an increase of 39%.

Business volume generated by research projects during the fiscal year amounted to $63.3 million. This year, Génome Québec managed projects under nine competitions, the largest being Personalized Health and the new Fonds de partenariat pour un Québec innovant et en santé (FPQIS).

The budget for projects underway totals $265 million, $92 million of which is still to be carried out.

GÉNOME QUÉBEC AND INVESTMENT ACTIVITIES

2014 - 2015





For the year ended on March 31, 2015, sales from our technology centres totalled $16.5 million, up 8% compared to last year. The technology centres posted an excess of revenues over expenses of $1.4 million. The cumulative surplus of the McGill University and Génome Québec Innovation Centre totalled $2.9 million at the end of the year, an amount to be turned over to the institution in the coming fiscal year.

General and administrative expenses, communications and outreach costs and committee expenses totalled $3.5 million this year. While this means an 11.1% increase compared to last year, these expenses represent 4.5% of total investments versus 5.3% last year. The increase is primarily due to expenses associated with the new FPQIS competition. Investment revenue reached $352,000, for a return of 1.62%.

During the fiscal year, the excess of revenues over expenses totalled $522,000. Non-designated net assets rose by $361,000, and $1.2 million were attributed to activities, for a sum of $2.3 million on March 31, 2015. Net assets totalling $500,000 have once again been earmarked for the contingency and technological development funds, and a sum of $1.2 million has been set aside for activities related to research, commercialization of research results and researcher support.

Finally, Génome Québec has respected the terms and conditions in compliance with the contractual agreements it has signed with its major financial partners.

Marc LePage
President and CEO
Génome Québec

Claude Lamarre
Vice President, Finance
Génome Québec

FINANCIAL STATEMENTS

STATEMENTS OF FINANCIAL POSITION

The Statements of Financial Position as at March 31, 2015 and 2014 and the Statement of Operations for the years ended March 31, 2015 and 2014 that follow are provided as illustrative summaries only and are not intended to replace the full financial statements of Génome Québec. These full financial statements, available in French only, were audited and reported on June 23, 2015 by KPMG L.L.P., Chartered Professional Accountants.

MARCH 31, 2015 WITH COMPARATIVE INFORMATION FOR 2014	2015	2014
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	$ 3 150 768	$ 3 702 844
Short-term investments	18 335 864	16 136 129
Accounts receivable and work in progress	2 901 065	2 380 689
Advances to genomic research projects	4 444 407	5 278 782
Inventories	1 749 723	1 287 646
Prepaid expenses	201 744	314 985
	30 783 571	**29 101 075**
LONG-TERM INVESTMENTS	3 306 085	5 446 577
CAPITAL ASSETS	644 174	568 006
	$ 34 733 830	**$ 35 115 658**
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	$ 4 130 914	$ 4 586 213
Deferred revenues	427 083	101 765
Obligations related to an agreement	2 897 793	920 000
	7 455 790	**5 607 978**
OBLIGATIONS RELATED TO AN AGREEMENT	-	1 339 512
DEFERRED CONTRIBUTIONS		
Future expenses	22 620 309	23 383 770
Capital assets	567 572	429 210
	23 187 881	**23 812 980**
	30 643 671	**30 760 470**
NET ASSETS		
Unrestricted	2 348 823	3 184 860
Restricted – Invested in capital assets	76 602	138 796
Restricted – Technology investment and contingency fund	500 000	500 000
Restricted – Research Projects	1 164 734	531 532
	4 090 159	**4 355 188**
	$ 34 733 830	**$ 35 115 658**

STATEMENT OF OPERATIONS

YEARS ENDED MARCH 31, 2015 AND 2014	2015	2014
REVENUES		
Amortization of deferred contributions related to expenses	$ 44 150 059	$ 36 136 816
Amortization of deferred contributions related to capital assets	217 735	214 489
Investment income	352 254	595 890
Revenues from technology centres	16 501 635	15 285 216
Other revenues	713 116	102 288
	61 934 799	**52 334 699**
EXPENSES		
Genomic research projects	24 341 632	27 443 262
Research projects, Innovative, Healthy Québec	11 846 340	165 605
Technology centres operational costs	20 829 683	20 458 242
Projects – Technology investment and contingency fund	640 000	664 465
General and administrative	2 765 912	2 638 481
General and administrative, Innovative, Healthy Québec	314 037	27 776
Communications and public outreach	368 691	369 486
Committees	26 810	91 553
Gain on capital assets disposal	-	(69 478)
Depreciation of capital assets	217 735	214 489
Depreciation of restricted capital assets	62 194	113 142
	61 413 034	**52 117 023**
EXCESS OF REVENUES OVER EXPENSES	$ 521 765	$ 217 676

BOARD OF DIRECTORS, COMMITTEES, EMPLOYEES

BOARD OF DIRECTORS

Chair of the Board
Martin Godbout, PhD

Vice Chairman of the Board
Daniel Bouthillier, PhD, MBA
Chief Executive Officer, Québec Network for Personalized Health Care (QNPHC)

Secretary Treasurer of the Board
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

BOARD MEMBERS

Hélène Desmarais, C.M., LL.D.
CEO and Chair of the Board of Administration, Centre d'entreprises et d'innovation de Montréal

Thomas J. Hudson, MD
President and Scientific Director, Ontario Institute for Cancer Research

Marc LePage
President and CEO, Génome Québec

Marie-Lucie Morin

Rémi Quirion, PhD, CQ, O.C., FRSC
Chief Scientist of Québec, Fonds de recherche du Québec (FRQ)

François R. Roy
Corporate Director

Jacques Simoneau, PhD
President and CEO, Univalor

Paule Têtu, F. Eng., MSc
Associate to the Vice President Research and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

Suzanne Vinet

Brian White-Guay, MD, FRCPC
Professor, Faculty of Pharmacy, Université de Montréal

OBSERVERS

Jean Belzile, PhD
Assistant Deputy Minister, Ministère de l'Économie, de l'Innovation et des Exportations

Pierre Meulien, PhD
President and CEO, Genome Canada

FINANCE COMMITTEE

Committee Chair
Daniel Bouthillier, PhD, MBA
Chief Executive Officer, QNPHC

François R. Roy
Corporate Director

Jacques Simoneau, PhD
President and CEO, Univalor

GOVERNANCE COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
Chief Executive Officer, QNPHC

Marc LePage
President and CEO, Génome Québec

Jacques Simoneau, PhD
President and CEO, Univalor

NOMINATION COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Marc LePage
President and CEO, Génome Québec

Marie-Lucie Morin

Paule Têtu, F. Eng., MSc
Associate to the Vice President Research and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

HUMAN RESOURCES COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Marc LePage
President and CEO, Génome Québec

Rémi Quirion, PhD, CQ, O.C., FRSC
Chief Scientist of Québec, Fonds de recherche du Québec (FRQ)

Paule Têtu, F. Eng., MSc
Associate to the Vice President Research and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

EXECUTIVE COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
Chief Executive Officer, QNPHC

Marc LePage
President and CEO, Génome Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President Research and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

MANAGEMENT COMMITTEE

Marc LePage
President and CEO

Marie-Kym Brisson
Vice President, Public Affairs and Communications

Claude Lamarre
Vice President, Finance

Catalina López Correa
Vice President, Scientific Affairs

Ève-Stéphanie Sauvé
Director, Human Resources and Legal Service

Daniel Tessier
Vice President, Technology Centres

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

Committee Chair
Louise Proulx, PhD
Therilia inc., Canada

Martine Dubuc, DVM
Canadian Inspection Food Agency, Canada

Michel Goldman, PhD
Université libre de Bruxelles, Belgium

Karl (Chuck) Hasel, PhD, MBA
Hasel Consulting, United States

Antoine Kremer, PhD
French National Institute for Agricultural Research (INRA), France

Teri Manolio, MD, PhD
National Human Genome Research Institute (NHGRI), United States

Mark McCarthy, PhD
Wellcome Trust, United Kingdom

Michael Müller, PhD
Norwich Research Park Food and Health Alliance (FAHA), United Kingdom

ADMINISTRATIVE CENTRE

Micheline Ayoub
Line Benguerel
Diane Bouchard
Marie-Kym Brisson
Christine Cellier
Cristina Ciurli
Hélène Fournier
Marie Garand
Nathaly Hébert
Nicolas Hoffmann
Éva Kammer
Danielle Kemmer
Claude Lamarre
Fabienne Lefebvre
Marc LePage
Darie Lessard
Ginette Levasseur
Catalina López Correa
Christine Martens
Ève-Stéphanie Sauvé
Louise Thibault
Vincent Trudel
Tu Linh Van

TECHNOLOGY CENTRES

René Allard
Steve Arsenault
Vicky Arsenault
François-Marie Bacot
Alexandre Bélisle
Carolina Bocanegra
Julie Boudreau
Mathieu Bourgey
Guillaume Bourque
Geneviève Bourret
Sébastien Brunet
Valérie Catudal
Patrice Charbonneau Larose
Catherine Côté
Geneviève Dancausse
Philippe Daoust
Haig Djambazian
Geneviève DonPierre
Nathalie Émond
Joëlle Fontaine
Rosalie Fréchette
Geneviève Geneau
Philippe Gingras Gélinas
Daniel Guertin
Isabelle Guillet
Alexandru Guja
Nathalie Hamel
Louis Dumond Joseph
François Korbuly
Audrey Ann Kustec
Sylvie LaBoissière
Marc-André Labonté
François Lefebvre
Pierre Lepage
Louis Létourneau
Gary Leveque
Pascale Marquis
François Massé
Aurélie Masurel
Terrance McQuilkin
Marc Michaud
Jana Mickova
Alexandre Montpetit
Thuong Ngo
Frédérick Robidoux
Sharen Sophie Roland
Virginie Saillour
Johanna Sandoval
Élyane Simard
Janick St-Cyr
Alfredo Staffa
Daniel Tessier
Belisle Tir
Thay Leng Tony Tir
Annie Verville
Daniel Vincent
Hoai-Thu Vo
Patrick Willett
Hao Fan Yam
Corine Zotti

FONDS DE PARTENARIAT POUR UN QUÉBEC INNOVANT ET EN SANTÉ (FPQIS)

Marie-Paule Choquette
Alina Cristea Birsanu
Stéphanie Lord-Fontaine
Julie Vallée

Announcement in London of a scientific and academic partnership between Université Laval and Oxford University with the Québec Prime Minister Philippe Couillard

Génome Québec's team at La Boucle du Grand défi Pierre Lavoie

Génome Quebec's team at the Défi Gratte-ciel

Holiday Celebration - December 2014

LARGE-SCALE PROJECT OUTCOMES

	Number of persons employed in the 4th Quarter 2014-2015	Number of scientists trained in the 4th Quarter 2014-2015	Number of publications accepted or submitted	Number of conferences as speaker	Number of declaration of invention or patents	Project starting date
ABC COMPETITION						
Thomas Bureau - McGill VEGI (Crop Improvment)	COMPLETED	COMPLETED	5	19	3	October 2009
Adrian Tsang - UConcordia Genozymes (Bioproducts and Bioprocesses Development)	COMPLETED	COMPLETED	6	12	13	October 2009
Peter Facchini - UAlberta / Vincent Martin - UConcordia Phytometasyn (Synthetic Biosystems for the Production of High Value Plant Metabolites)	COMPLETED	COMPLETED	2	12	6	October 2009
Richard Gold - McGill Valgen (Value Addition Through Genomics)	COMPLETED	COMPLETED	6	2	0	October 2009
TOTAL	**0**	**0**	**19**	**45**	**22**	
2010 COMPETITION						
LARGE-SCALE APPLIED RESEARCH PROJECTS						
John MacKay - ULaval / Jörg Bohlman - UBritishColumbia SMarTForest (Sustainable Forestry)	37,5	12	26	35	0	July 2011
B. Franz Lang / Mohamed Hijri - UMontreal GenoRem (Decontaminating Soils)	22	29	29	30	0	July 2011
TOTAL	**59,5**	**41**	**55**	**65**	**0**	
ENTREPRENEURSHIP PROGRAM						
EDUCATION IN GENOMICS						
Denis J. Garand - ULaval BEST in Genomics! (Optimize the transfer of Knowledge)	COMPLETED	COMPLETED	0	1	0	October 2011
TOTAL	**0**	**0**	**0**	**1**	**0**	

GQ HEALTH COMPETITION*

Gregor Andelfinger - CHU Ste-Justine Congenital Heart Disease	COMPLETED	COMPLETED	2	1	0	October 2010
Guy A. Rouleau - CHUM Bipolar Disorder	COMPLETED	COMPLETED	0	0	0	October 2010
Guy Sauvageau - IRIC Acute Myeloid Leukemia	COMPLETED	COMPLETED	0	0	0	October 2010
John H. White - McGill Tuberculosis	COMPLETED	COMPLETED	0	0	0	October 2010
Ken Dewar - McGill Digestive Problems	COMPLETED	COMPLETED	0	0	0	October 2010
Mark Basik - Lady Davis Institute Breast Cancer	6	1	1	1	0	October 2010
Michael Hallet - McGill Breast Cancer	COMPLETED	COMPLETED	3	3	0	October 2010
Alain Moreau - CHU Ste-Justine Diagnostic Tool for Pediatric Scoliosis	COMPLETED	COMPLETED	1	1	0	October 2010
Michel G. Bergeron - ULaval Rapid Diagnostic Tests	COMPLETED	COMPLETED	0	0	0	October 2010
Maryam Tabrizian - McGill Portative Biosensors	COMPLETED	COMPLETED	2	1	0	October 2010
Paul Goodyer - CUSM Cell Therapy of Cystinosis	COMPLETED	COMPLETED	0	0	0	October 2010
Pavel Hamet - CHUM Type 2 Diabetes	COMPLETED	COMPLETED	0	0	0	October 2010
Gordon Shore / Michel L. Tremblay - McGill Cancer Therapy	COMPLETED	COMPLETED	0	1	0	October 2010
TOTAL	**6**	**1**	**9**	**8**	**0**	

The results presented above reflect only the actual impact for financial year 2014-2015. The cumulative impact from this competition (among which 12 projects out of 13 are terminated) will be presented for all the projects in next year's annual report.

2012 COMPETITION

LARGE-SCALE APPLIED RESEARCH PROJECTS / PERSONALIZED HEALTH

Claude Perreault - HMR Immunotherapy (Cancer)	19,5	2	1	1	2	April 2013
Patrick Cossette - CHUM Epilepsy	10,9	1	3	2	0	April 2013
Guy Sauvageau - UMontreal Leucegene GC (Acute Myeloid Leukemia)	36,3	5	2	5	5	April 2013
Francois Rousseau - ULaval PEGASUS (Prenatal Aneuploidy Screening Using Maternal Blood)	36	7	7	18	0	April 2013
Jacques Simard - ULaval Breast Cancer (Prevention and Early Detection)	20,2	5	11	39	0	April 2013
John Rioux - ICM iGenomed (Inflammatory Bowel Diseases)	16	0	0	4	0	April 2013
Jean-Claude Tardif - ICM Cardiovascular Diseases (Targeted Therapeutics)	24,4	3	5	4	0	April 2013
Nada Jabado - CUSM Research Institute iChange (Pediatric Brain Cancer)	19,1	9	5	29	0	April 2013
Sin - UBritish Columbia / MacNamara, Bourbeau - McGill / Awadalla - UMontreal / Maltais - ULaval COPD (Disease Management)	0,2	0	3	19	0	April 2013
Harrigan - UBritish Columbia / Charest, Tremblay - INSPQ / Roger - UMontreal / Wainberg - McGill AIDS (Response to Therapies)	0,5	0	2	2	0	April 2013
McCabe - UAlberta / Gold, Kimmelman - McGill PACE-'Omics (GE3LS, Personalized Medicine Adoption)	1,4	0	10	30	0	April 2013
Boycott - UOttawa / Bernard, Brais, Knoppers, Majewski - McGill / Michaud, Samuels - UMontreal CARE for RARE (Rare Genetic Diseases in Canada)	2,8	0	9	10	0	April 2013
TOTAL	**187,3**	**32**	**58**	**163**	**7**	

2012 COMPETITION

BIOINFORMATICS AND COMPUTATIONAL BIOLOGY

Jérome Waldispuhl - McGill Science games in genomics	3	5	1	0	0	July 2013
Mathieu Blanchette - McGill PIATEA	1,8	1	0	0	0	July 2013
Anne-Claude Gingras - Samuel Lunenfeld Research Institute / Mike Tyers - UMontreal ProHits Next Generation	2	0	1	9	0	July 2013
TOTAL	**6,8**	**6**	**2**	**9**	**0**	

RECRUITEMENT COMPETITIONS

DIRECTOR CARTAGENE

Philip Awadalla - CHU Ste-Justine CARTaGENE	COMPLETED	COMPLETED	9	7	0	January 2010

HUMAN HEALTH

Mike Tyers - UMontreal Biological Network in Human Health	32,3	8	8	3	1	April 2011
Mark Lathrop - McGill Medical Genomics	9	2	45	3	0	April 2011
TOTAL	**41,3**	**10**	**62**	**13**	**1**	

PARTNERSHIP PROGRAM

GENOMIC APPLICATION PARTNERSHIP PROGRAM (GAPP)

Steve Labrie - ULaval Metagenomic and Cheesemaking Technologies	2,6	0	0	2	0	April 2014
Adrian Tsang - UConcordia Enzymes Supplement for Swine and Poultry	15,8	0	0	0	0	October 2014
Hamelin - UBritish Columbia / Roger Lévesque - ULaval - IBIS Next Generation Biosurveillance of Invasive Alien Species	0,3	0	0	0	0	October 2014
TOTAL	**18,7**	**0**	**0**	**2**	**0**	

PROGRAM

FONDS DE PARTENARIAT POUR UN QUÉBEC INNOVANT ET EN SANTÉ

Gerald Batist - JGH Personalized Health Care Network Q-CROC	28,8	0	1	5	0	April 2014
Michel Bergeron - CHU de Qc Rapid Diagnostic Test	14,6	0	2	1	0	April 2014
Michel Bouvier - IRIC (IRIC-Industry) Drug Discovery	52,5	0	3	11	0	April 2014
Nicola Hagemeister - ÉTS Arthritis of the Knees (Diagnostic and Treatment)	3,6	0	0	3	0	October 2014
Pavel Hamet - CHUM (OPTI-THERA) Optimization of the Therapeutics Approaches in Primary Care	25,3	1	16	20	0	April 2014
Jean-Claude Tardif - ICM (ARTERIA) Cardiovascular Personalized Diagnostics and Therapies	29,4	0	1	0	0	April 2014
Brian Ward - CUSM Vaccines Produced in Plant Against Viral Pneumonia	22,8	7	3	8	0	April 2014
TOTAL	**177**	**8**	**26**	**48**	**0**	

TOTAL COMPETITIONS ***ONGOING PROJECTS***	**496,6**	**98**	**231**	**354**	**30**

ASSESSMENT OF COMPLETED PROJECTS

	Number of persons employed in year-person	Number of researcher trained in year-person	Number of publications accepted or submitted	Number of lectures as a lecturer	Number of invention disclosure or patents	Duration of the project in years
QUÉBEC VERT COMPETITION						
François Belzile - ULaval GreenSNPs (Environmental Genomics)	5,6	2	4	9	0	2
Connie Lovejoy - ULaval CATG (Genomics for Arctic Environment)	4,2	1,2	0	3	0	1,5
Vincent Martin - UConcordia PAYGE (Reducing Fuel Dependency)	2,6	0	0	0	0	2
PILOT PROJECTS GQ COMPETITION						
Jamie Engert - CUSM Heart Disease	3	0	0	0	0	2
Julie St-Pierre - McGill Breast Cancer	3	2	1	1	0	2
Pierre Drapeau / Edor Kabashi - UMontreal New Therapeutic Approaches	3	2	3	12	1	2
Roger C. Levesque - ULaval Budwork EcoGenomic	3,4	1	3	15	0	2
Sarah Kimmins - McGill Infertility	4,3	2	2	9	0	2
Zoha Kibar - CHU Ste-Justine Neural Tube Defects	0,8	1	0	0	0	2
COMPETITIONS I & II						
HEALTH						
Michel G. Bergeron - CHUQ Theranostic Technologies (Diagnostic Tests to Identify Microbes Causing Infections)	118	25	25	58	11	3,25
Deming Xu - Private Chemogenomics (New Therapeutic Treatments for Life-Threatening Fungal Infections)	32	2	8	4	1	3
Thomas J. Hudson - McGill ARCTIC (Colorectal Cancer)	42	6	19	15	9	3,25
Franz Lang - UMontreal Protist EST (Evolution of Eukaryotic Cells' and Corresponding Genes)	49	21	20	18	0	3,5
Bussey / Michnick - McGill Model Organisms (Genetic Interaction in Eukaryotic Cells)	20	4	18	55	0	4

John J.M. Bergeron - McGill Proteomics (Function and Structure of Genes and Proteins)	174	67	42	125	7	4
Fernand Labrie - ULaval Atlas (Profiles of Steroid Action)	347	120	49	29	2	5
Bartha Maria Knoppers - McGill GE^{3}LS (Genomics and Society)	38	20	83	153	0	4
Fathey Sarhan - UQAM Abiotic Stress Québec (Improve Agricultural Productivity)	82	28	11	17	0	4
Thomas J. Hudson - McGill Regulatory Genetics (Identification of Regulatory Polymorphisms in the Human Genome)	117	27	16	51	6	4
Rafick-Pierre Sékaly - UMontreal S2K (Immune Response)	194	79	17	150	6	4
Mario Fillion - McGill IGWH (Women's Health)	36	5	1	10	4	3
Sherif Abou Elela - USherbrooke MoNa (Genome Wide Analysis of Gene Function)	51	8	6	9	2	3
Adrian Tsang - UConcordia Fungal Enzymes (Environmental Remediation)	167	69	16	22	8	3
Benoît Coulombe - UMontreal Regulatory Networks (Decode Genetic Information)	189	63	15	111	0	3,5
John MacKay - ULaval Arborea I (Health of Trees)	98	31	23	63	2	3,5
Thomas J. Hudson - McGill HapMap (Genetic Research)	34	2	14	87	1	3
Emil Skamene - McGill Congenic Mice (Dirrect Complex Traits Relevant to Human Health)	60	13	2	11	3	4,25
Guy Rouleau - UMontreal Ionic Channels (Hereditary Neurological Disorder)	40	5	0	16	3	4,25
Terry Roemer - Private Candida Albicans (Antifungical Drug Discovery)	51	0	2	3	3	3
Barry Posner / Rob Sladek - McGill Type 2 Diabetes	5	0	25	35	6	5,5
Bartha Maria Knoppers - McGill GPH (Genomic and Public Health)	5	4	22	47	0	January 2006

COMPETITION III

INTERNATIONAL CONSORTIUM INITIATIVE, PRIVAC, TECHNOLOGY DEVELOPMENT COMPETITION

Sherif Abou Elela - USherbrooke FAESI (Alternative Splicing)	101,5	10,8	11	28	3	5,25
Ken Dewar - McGill Vervet Monkey (Neuro-Development and Neurological Deterioration)	18,3	2	3	4	0	4,75
Tomi M. Pastinen - McGill GRID (Genes Regulators)	213	51,5	84	42	2	4,5
Guy A. Rouleau - UMontreal S2D (Brain Disease)	86	12	14	41	1	5
Jean-Claude Tardif - ICM Pharmacogenomics (Cardiovascular Disease)	346	41	15	87	0	4
John MacKay - ULaval Arborea II (Improve Productivity of Forests Products)	186	66,6	49	95	0	5
Bartha Maria Knoppers / Thomas J. Hudson - McGill P3G/CaG (Populations Genomics)	33,5	24	35	54	0	3
Daniel Lamarre / Sylvain Meloche - IRIC RNA Platform (New Targeted Therapies for Cancer)	16,8	0	0	3	0	2
Rafick-Pierre Sékaly - UMontreal NIML Platform (Vaccines and Immune Therapeutics)	18	3	4	5	2	2
Michel G. Bergeron - CHUQ GPOCT (Infectiology)	45	2	9	18	1	2,25
Michael Phillips / Jean-Claude Tardif - ICM Via-PGX (Cardiovascular Pharmacogenomics)	17,5	3,6	4	44	0	2,5
Maryam Tabrizian - McGill DevTab (Biomarkers Discovery and Validation)	35,3	15,2	34	13	0	2
Rafick-Pierre Sékaly / Ryan Brinkman - UMontreal - BCCA DevSek (Immune System)	6	1	2	4	0	2
TOTAL COMPLETED PROJECTS	**3 102**	**843**	**711**	**1 576**	**84**	

GenomeQuébec

630 René-Lévesque Blvd. West, Suite 2660
Montréal, Québec H3B 1S6

genomequebec.com

@GenomeQC

@GenomeQuebec